Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease

Show other versions (1)

Bibliographic Details
Main Authors:	Bekker, P, Hamilton, G, Johnson, D, Keshav, S, Schall, T
Format:	Conference item
Published:	2008

Similar Items

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
by: Bekker, P, et al.
Published: (2008)

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
by: Bekker, P, et al.
Published: (2007)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009)

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
by: Bekker, P, et al.
Published: (2008)

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
by: Keshav, S, et al.
Published: (2007)

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis
by: Wei, Z, et al.
Published: (2005)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
by: Keshav, S, et al.
Published: (2007)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
by: Ungashe, S, et al.
Published: (2008)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
by: Walters, M, et al.
Published: (2010)

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease
by: Bekker, P, et al.
Published: (2007)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
by: Wendt, E, et al.
Published: (2015)

Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study
by: Yao He, et al.
Published: (2017-05-01)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
by: Martyna Szczubełek, et al.
Published: (2021-11-01)

Probiotics in Crohn's disease remission: a systematic review
by: Kamilla Pontes Azevedo, et al.
Published: (2022-03-01)

704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
by: Qingfeng Zhu, et al.
Published: (2023-11-01)

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
by: Jan Korbecki, et al.
Published: (2020-10-01)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
by: Tobias Puengel, et al.
Published: (2022-06-01)

Ustekinumab and remission in perianal Crohn's disease: A case report
by: C.E. Alcántara-Figueroa, et al.
Published: (2023-10-01)

Induction of remission with oral budesonide MMX (R) (9 mg) tablets in oatients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study
by: Travis, S, et al.
Published: (2011)

Effects of Crohn’s disease exclusion diet on remission: a systematic review
by: Zhanhui Zhu, et al.
Published: (2023-08-01)

Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA
by: Nanhua Zhang, et al.
Published: (2024-03-01)

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
by: Steinhart, A, et al.
Published: (2007)

Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn’s Disease
by: Gaurav Agrawal, et al.
Published: (2020-07-01)

How Can a Polymeric Formula Induce Remission in Crohn’s Disease Patients?
by: Kawthar Boumessid, et al.
Published: (2021-04-01)

HOW IS THE DIET QUALITY OF PATIENTS WITH CROHN’S DISEASE IN CLINICAL REMISSION USING INFLIXIMAB?
by: Melissa Mercadante Santana CRUZ, et al.
Published: (2021-10-01)

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
by: S. Bowler, et al.
Published: (2019-09-01)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
by: M. Tocco, et al.
Published: (2021-04-01)

The role of CCL25 and CCR9 in intestinal inflammation
by: Wendt, E, et al.
Published: (2013)

Medical management of Crohn's disease.
by: Cummings, JR, et al.
Published: (2008)

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort studyResearch in context
by: Mariangela Allocca, et al.
Published: (2024-05-01)

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
by: Gupta, R, et al.
Published: (2019)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
by: Jairath, V, et al.
Published: (2016)

Adalimumab induction therapy achieves clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2015)

Micronutrient Status in Adult Crohn’s Disease during Clinical Remission: A Systematic Review
by: Martin McDonnell, et al.
Published: (2023-11-01)

Sustained Crohn’s Disease Remission with an Exclusive Elemental and Exclusion Diet: A Case Report
by: Farhad Mehrtash
Published: (2021-08-01)

Induction of Remission in Pediatric Crohn’s Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index
by: Roma Herman, et al.
Published: (2021-11-01)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
by: Juntao Yin, et al.
Published: (2022-09-01)

Exploring the concept of deep remission in Crohn’s disease: correlation between transmural healing and biomarkers
by: Fabiana Castiglione, et al.
Published: (2022-07-01)

In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
by: Bayry, J, et al.
Published: (2008)